Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like A Look at the Deaths That Plagued Juno and Kite Pharma's CAR-T Trials June 26, 2017 Newron Pharma Shareholders Confirm Company Management March 27, 2017 InVivo Therapeutics To Present At s 37th Annual Growth Conference August 7, 2017
